Endocrine Metabolic & Immune Disorders-Drug Targets
metrics 2024
Advancing Knowledge, Transforming Therapies
Introduction
Endocrine Metabolic & Immune Disorders-Drug Targets, published by Bentham Science Publishers, is a premier journal focused on the intricate interplay between endocrinology, metabolism, and immune response, with a particular emphasis on drug targets. Established in 2006 and set to continue its influence until 2024, this journal serves as a crucial platform for researchers and professionals to communicate significant advances in understanding metabolic and immune disorders, making it an invaluable resource in the realms of Endocrinology and Immunology. With an impact factor positioned within the Q3 category for both Endocrinology, Diabetes and Metabolism, and Immunology and Allergy as of 2023, the journal stands at the crossroads of critical research and clinical application, facilitating ongoing dialogue among the scientific community. Although currently not open access, its dedication to high-quality peer-reviewed articles ensures that cutting-edge research remains accessible to those invested in enhancing therapeutic strategies. For researchers and practitioners alike, Endocrine Metabolic & Immune Disorders-Drug Targets is an essential conduit for the latest findings that can influence treatment paradigms and bolster the understanding of complex biological systems.
Metrics 2024
Metrics History
Rank 2024
Scopus
IF (Web Of Science)
JCI (Web Of Science)
Quartile History
Similar Journals
Journal of the Endocrine Society
Bridging gaps in understanding diabetes and metabolism.Journal of the Endocrine Society, published by the ENDOCRINE SOC, stands as a prominent platform for disseminating significant research and findings within the field of endocrinology, diabetes, and metabolism. Established as an Open Access journal since 2017, it aims to increase the visibility and accessibility of vital scholarly contributions, allowing researchers and professionals from various backgrounds to engage with the latest insights in this rapidly evolving discipline. With an impressive Q2 ranking in Endocrinology, Diabetes and Metabolism, the journal is recognized for its impact, ranking #100 out of 244 in Scopus, highlighting its role in advancing scientific knowledge and fostering innovation. The journal, based in the United States at 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036, continues to enrich the academic landscape by converging state-of-the-art research and clinical applications through its publication cycle from 2017 to 2024. Researchers, students, and healthcare professionals are encouraged to explore this essential resource to stay at the forefront of endocrinological advancements.
Frontiers in Endocrinology
Empowering Science Through Open Access in EndocrinologyFrontiers in Endocrinology, published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to the advancement of research in the fields of endocrinology, diabetes, and metabolism. Established in 2010, this journal has consistently demonstrated its academic excellence, achieving a prominent Q1 quartile ranking in its category as of 2023, and a commendable Scopus rank of #96 out of 244, placing it within the 60th percentile. The journal is committed to disseminating high-quality research that encompasses a wide range of topics within endocrinology, catering to the needs of a diverse audience that includes researchers, medical professionals, and students alike. With the critical goal of fostering knowledge-sharing and collaboration within the scientific community, Frontiers in Endocrinology is an invaluable resource for anyone looking to stay updated on the latest advancements and insights in endocrinology. It operates under a robust open-access model, ensuring that groundbreaking research is accessible to all, thereby driving innovation and progress in this essential field.
Turkish Journal of Endocrinology and Metabolism
Advancing Global Knowledge in Endocrinology and MetabolismThe Turkish Journal of Endocrinology and Metabolism, published by AVES, is a prominent platform dedicated to advancing research in the fields of endocrinology, diabetes, and metabolism. As an Open Access journal since 2002, it provides unrestricted access to its content, fostering a global exchange of knowledge among researchers, clinicians, and students. Operating from Turkey, this journal plays a crucial role in disseminating innovative findings related to endocrine disorders and metabolic diseases. While its current Q4 quartile rankings in both Endocrinology and Internal Medicine underscore areas for growth, they also signify the journal’s commitment to enhancing its impact within these disciplines. The journal emphasizes the development of locally relevant research while encouraging international contributions, thus bridging gaps in global health discourse. Engage with cutting-edge research that shapes clinical practices and informs public health policies by submitting your work or exploring the journal’s vast archive from 2009 to 2023.
Minerva Endocrinology
Exploring New Horizons in Endocrine ResearchMinerva Endocrinology, published by EDIZIONI MINERVA MEDICA in Italy, serves as a pivotal platform for advancing knowledge in the field of endocrinology, diabetes, and metabolism. With its ISSN 2724-6507 and E-ISSN 2724-6116, the journal has rapidly established a reputable position in academia, achieving impressive rankings such as Q3 in both Endocrinology and Diabetes and Metabolism, and Q2 in Internal Medicine as of 2023. This enables Minerva Endocrinology to attract a diverse readership, including researchers, healthcare professionals, and students committed to understanding the complexities of endocrine disorders. With annual publications covering breakthroughs and innovative research covering converged years from 2021 to 2024, the journal is devoted to facilitating the dissemination of high-quality studies that advance clinical and laboratory practices. Despite its >Open Access< status, the journal encourages submissions that reflect rigorous scientific inquiry and uphold the highest standards of scholarship, thereby enhancing its role as a significant contributor to the field of internal medicine and endocrinology.
Immunity Inflammation and Disease
Exploring innovative insights in immunology and allergy.Immunity, Inflammation and Disease is a premier open-access journal published by WILEY, dedicated to advancing the field of immunology and allergy. Launched in 2013, this journal has established itself as a significant platform for researchers and professionals to disseminate high-quality research findings and innovative insights that address critical issues in immune responses and inflammatory diseases. With an impact factor that reflects its growing influence and a current ranking in Q3 for Immunology and Q2 for Immunology and Allergy, this journal serves a diverse audience keen on exploring cutting-edge developments. Researchers are encouraged to submit their work to share their findings with a global reach, foster collaboration, and enhance the understanding of immune mechanisms and therapeutic strategies. Accessible since its inception, Immunity, Inflammation and Disease is committed to open science, ensuring that vital research is freely available for the advancement of knowledge within the academic community and beyond.
Endocrinology Diabetes and Metabolism Case Reports
Empowering Research with Open Access DiscoveriesEndocrinology Diabetes and Metabolism Case Reports, published by BIOSCIENTIFICA LTD, stands as a pivotal forum for sharing significant advancements and clinical case studies in the fields of endocrinology, diabetes, and metabolism. With an Open Access model initiated in 2013, this journal encourages the widespread dissemination and accessibility of research findings, promoting collaboration and innovation among scholars and healthcare professionals. Based in the United Kingdom, the journal features a focus on practical applications and unique case reporting that enriches the clinical understanding and management of complex endocrine disorders. Though currently it's ranked in the Q3 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine, its ongoing commitment to quality and impact in clinical research makes it a valuable resource for researchers, professionals, and students alike, contributing to the advancement of knowledge in this critical medical domain.
Acta Endocrinologica-Bucharest
Nurturing emerging ideas in endocrinology and metabolism.Acta Endocrinologica-Bucharest is a vital resource for those engaged in the study and practice of endocrinology, diabetes, and metabolic research. Published by EDITURA ACAD ROMANE, this journal emphasizes the dissemination of high-quality research and insights specific to the fields of endocrinology and autonomic systems. Although categorized in the lower quartiles of its subject areas according to the latest rankings—Q4 in Endocrine and Autonomic Systems and Q4 in Endocrinology—it serves as an important platform for emerging scientific ideas and collaborative studies within the endocrinology community. With an ISSN of 1841-0987 and an E-ISSN of 1843-066X, the journal provides a significant opportunity for authors to contribute to the growing body of knowledge in these fields from its base in Romania. Researchers and practitioners alike will find valuable contributions that reflect both contemporary challenges and advances in endocrinology, reinforcing the journal's commitment to enhancing scholarly communication.
Austrian Journal of Clinical Endocrinology and Metabolism
Bridging research and practice in metabolic health.Austrian Journal of Clinical Endocrinology and Metabolism, published by SPRINGER WIEN, serves as a pivotal platform for the dissemination of research in the field of endocrinology, diabetes, and metabolism. With its ISSN 1998-7773 and E-ISSN 1998-7781, this journal has been contributing valuable insights to the field since its inception in 2010. Although it currently holds a Q4 ranking in the category of Endocrinology, Diabetes and Metabolism, it is committed to improving its impact factor by showcasing high-quality, peer-reviewed articles that reflect contemporary challenges and innovations in clinical endocrinology. Located in Vienna, Austria, the journal aims to provide researchers, healthcare professionals, and students with access to the latest findings and clinical practices that advance understanding and treatment of endocrine disorders. Researchers interested in submitting their work will find a supportive environment that embraces both experimental and clinical approaches. The Austrian Journal of Clinical Endocrinology and Metabolism is poised to become a valuable resource for those dedicated to improving health outcomes in metabolic disorders.
Journal of the ASEAN Federation of Endocrine Societies
Connecting Minds: Fostering Endocrine Research Across BordersWelcome to the Journal of the ASEAN Federation of Endocrine Societies, a pioneering publication dedicated to advancing knowledge and research in the fields of Endocrinology, Diabetes, and Metabolism. Established by the ASEAN Federation Endocrine Society and open access since 2011, this journal enhances the dissemination of critical findings and encourages collaboration among professionals and researchers across Southeast Asia and beyond. With an ISSN of 0857-1074 and E-ISSN of 2308-118X, the journal is indexed within Quartile 4 in the 2023 rankings of its categories, reflecting its commitment to providing a platform for scholarly work despite its emerging status. Situated in the Philippines, the journal focuses on the latest trends, treatments, and innovative research approaches in endocrinology, making it an essential resource for academics, clinicians, and students alike. We invite you to explore our content and contribute to advancing the endocrine sciences.
International Immunopharmacology
Connecting Researchers to the Future of Immune System ScienceInternational Immunopharmacology, published by Elsevier, stands as a prominent journal within the disciplines of immunology and pharmacology. With an ISSN of 1567-5769 and an E-ISSN of 1878-1705, this esteemed journal is based in the Netherlands and features a robust commitment to disseminating high-quality research from its inception in 2001 through 2024. The journal has achieved impressive rankings, securing a Q1 category in Pharmacology and Q2 in both Immunology and Immunology and Allergy as of 2023. With its strategic focus on bridging the gap between immunology and pharmacological applications, International Immunopharmacology attracts a diverse readership, including researchers, healthcare professionals, and students interested in the latest advancements in therapeutic agents and immune system modulation. Furthermore, it offers an open access option, enhancing the accessibility and reach of its invaluable content. As a pivotal resource in the field, this journal not only facilitates the exchange of innovative ideas but also fosters a deeper understanding of the complexities of immunopharmacology in today’s research landscape.